Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
nevirapine + emtricitabine + tenofovir
- Development stage
- Unknown
- Lead developer
- Gilead Sciences
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
This combination is used to treat HIV infection. **Nevirapine** is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that works by lowering the amount of HIV in the blood[7]. **Emtricitabine** and **tenofovir** are nucleoside reverse transcriptase inhibitors (NRTIs) that inhibit viral replication by competing with natural nucleotides and causing chain termination during viral DNA synthesis[1][6]. This combination is not a single branded product but rather a regimen of antiretroviral therapy.
- Brand names
- None identified; no single-tablet brand name for this exact combination.
- Other names
- nevirapine + tenofovir disoproxil + emtricitabine
02
Targets
Human immunodeficiency virus type 1 reverse transcriptaseHBV Pol (Hepatitis B virus polymerase)
Beyond the preview
Go deeper on nevirapine + emtricitabine + tenofovir.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on nevirapine + emtricitabine + tenofovir.